Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003009 · ClinicalTrials.gov registry record · Phase 1
Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer
A Phase 1 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00003009 is a Phase 1 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 16 participants.
The verdict
NCT00003009, a Phase 1 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Giving interleukin-2 in different ways may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of inhaled interleukin-2 in treating patients with metastatic or unresectable cancer.
Interventions
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 1996-02 |
| Est. Completion | 2000-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003009
The ClinicalTrials.gov registry entry for NCT00003009 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aldesleukin is the first listed.
NCT00003009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003009 about?
NCT00003009 is a clinical study titled "Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Giving interleukin-2 in different ways may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of inhaled interleukin-2 in treating patients with metastatic or unresectable cancer.
What is the current status of trial NCT00003009?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 1996-02. Estimated completion is 2000-08.
What interventions are being tested in trial NCT00003009?
The interventions under investigation include: aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003009?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.